DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
29 Janeiro 2024 - 6:13PM
Business Wire
DiaMedica Presents the Protocol and
Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute
Ischemic Stroke Ineligible for tPA and/or Mechanical
Thrombectomy
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company currently focused on developing
recombinant KLK1 (DM199) for the treatment of acute ischemic stroke
(AIS), today announced a poster presentation of the design and
rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199
in AIS patients, at the American Heart Association 2024
International Stroke Conference being held in Phoenix, AZ from
February 7 – 9, 2024. For information about the event, visit:
https://professional.heart.org/en/meetings/international-stroke-conference.
The DiaMedica poster is:
Poster Title: “Phase 2/3 Adaptive
Design, Randomized Double-blind Placebo-controlled Study To
Evaluate The Safety And Efficacy Of Dm199 For The Treatment Of
Acute Ischemic Stroke (ReMEDy2 Trial)”
The poster will be located in Poster Hall 5-6 (Poster Board
CTP36). On Thursday February 8, 2024, from 7:00 PM – 07:30 PM. Dr.
Scott Kasner, ReMEDy2 trial National Principal Investigator, will
be present to answer questions about the poster. Following the
session, a reprint of the poster will be accessible from
DiaMedica’s website at:
https://www.diamedica.com/investors/events-presentations.
DiaMedica will also be exhibiting at the conference located in
the main hall at booth 1021.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases with a focus on acute
ischemic stroke. DiaMedica’s lead candidate DM199 is the first
pharmaceutically active and clinically studied recombinant
(synthetic) form of the KLK1 protein, an established therapeutic
modality in Asia for the treatment of acute ischemic stroke and
other vascular diseases. For more information visit our website at
www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240129496878/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi Corporate Communications Phone: (508) 444-6790
ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
